Status:
UNKNOWN
Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.
Lead Sponsor:
Hospital Civil de Guadalajara
Conditions:
Metabolic Syndrome
HIV-1-infection
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
With current antiretroviral therapy, people living with HIV reach virological suppression faster, which in turn leads to a higher life expectancy. Nevertheless, this improved survival rate is not free...
Eligibility Criteria
Inclusion
- Age between 18 and 60 years
- Documented HIV-1 infection
- Stable antiretroviral therapy at least 6 months before enrollment
- Viral suppression
- Metabolic syndrome , defined by Adult Treatment Panel-III criteria
- No previously known kidney or liver disease
- Signed informed consent
Exclusion
- People younger than 18 years and older than 60 years
- Prior atherosclerotic cardiovascular disease
- Diabetes mellitus type 1 or 2
- Previous use of glucose and/or lipid modifying medications
- Pregnancy
- Withdrawal of informed consent
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04860063
Start Date
April 1 2021
End Date
July 1 2022
Last Update
April 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.